Increased sphingosine-1-phosphate improves muscle regeneration in acutely injured mdx mice

被引:46
作者
Ieronimakis, Nicholas [1 ]
Pantoja, Mario [2 ]
Hays, Aislinn L. [1 ]
Dosey, Timothy L. [2 ]
Qi, Junlin [2 ]
Fischer, Karin A. [2 ]
Hoofnagle, Andrew N. [3 ]
Sadilek, Martin [4 ]
Chamberlain, Jeffrey S. [5 ]
Ruohola-Baker, Hannele [2 ]
Reyes, Morayma [1 ,3 ]
机构
[1] Univ Washington, Dept Pathol, Sch Med, Seattle, WA 98195 USA
[2] Univ Washington, Inst Stem Cell & Regenerat Med, Dept Biochem, Seattle, WA 98195 USA
[3] Univ Washington, Dept Lab Med, Sch Med, Seattle, WA 98195 USA
[4] Univ Washington, Dept Chem, Seattle, WA 98195 USA
[5] Univ Washington, Dept Neurol, Senator Paul D Wellstone Muscular Dystrophy Coope, Seattle, WA 98195 USA
来源
SKELETAL MUSCLE | 2013年 / 3卷
关键词
DUCHENNE MUSCULAR-DYSTROPHY; SKELETAL-MUSCLE; SATELLITE CELLS; ENDOTHELIAL-CELLS; MEMBRANE-PROTEIN; NITRIC-OXIDE; EVANS BLUE; EXPRESSION; MOUSE; LYASE;
D O I
10.1186/2044-5040-3-20
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Background: Presently, there is no effective treatment for the lethal muscle wasting disease Duchenne muscular dystrophy (DMD). Here we show that increased sphingosine-1-phoshate (S1P) through direct injection or via the administration of the small molecule 2-acetyl-4(5)-tetrahydroxybutyl imidazole (THI), an S1P lyase inhibitor, has beneficial effects in acutely injured dystrophic muscles of mdx mice. Methods: We treated mdx mice with and without acute injury and characterized the histopathological and functional effects of increasing S1P levels. We also tested exogenous and direct administration of S1P on mdx muscles to examine the molecular pathways under which S1P promotes regeneration in dystrophic muscles. Results: Short-term treatment with THI significantly increased muscle fiber size and extensor digitorum longus (EDL) muscle specific force in acutely injured mdx limb muscles. In addition, the accumulation of fibrosis and fat deposition, hallmarks of DMD pathology and impaired muscle regeneration, were lower in the injured muscles of THI-treated mdx mice. Furthermore, increased muscle force was observed in uninjured EDL muscles with a longer-term treatment of THI. Such regenerative effects were linked to the response of myogenic cells, since intramuscular injection of S1P increased the number of Myf5(nlacz/+) positive myogenic cells and newly regenerated myofibers in injured mdx muscles. Intramuscular injection of biotinylated-S1P localized to muscle fibers, including newly regenerated fibers, which also stained positive for S1P receptor 1 (S1PR1). Importantly, plasma membrane and perinuclear localization of phosphorylated S1PR1 was observed in regenerating muscle fibers of mdx muscles. Intramuscular increases of S1P levels, S1PR1 and phosphorylated ribosomal protein S6 (P-rpS6), and elevated EDL muscle specific force, suggest S1P promoted the upregulation of anabolic pathways that mediate skeletal muscle mass and function. Conclusions: These data show that S1P is beneficial for muscle regeneration and functional gain in dystrophic mice, and that THI, or other pharmacological agents that raise S1P levels systemically, may be developed into an effective treatment for improving muscle function and reducing the pathology of DMD.
引用
收藏
页数:21
相关论文
共 80 条
  • [1] Dysferlin is a plasma membrane protein and is expressed early in human development
    Anderson, LVB
    Davison, K
    Moss, JA
    Young, C
    Cullen, MJ
    Walsh, J
    Johnson, MA
    Bashir, R
    Britton, S
    Keers, S
    Argov, Z
    Mahjneh, I
    Fougerousse, F
    Beckmann, JS
    Bushby, KMD
    [J]. HUMAN MOLECULAR GENETICS, 1999, 8 (05) : 855 - 861
  • [2] Aoki Masashi, 2005, Rinsho Shinkeigaku, V45, P938
  • [3] Increased connective tissue growth factor associated with cardiac fibrosis in the mdx mouse model of dystrophic cardiomyopathy
    Au, Carol G.
    Butler, Tanya L.
    Sherwood, Megan C.
    Egan, Jonathan R.
    North, Kathryn N.
    Winlaw, David S.
    [J]. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 2011, 92 (01) : 57 - 65
  • [4] Inhibition of Sphingosine-1-Phosphate Lyase for the Treatment of Autoimmune Disorders
    Bagdanoff, Jeffrey T.
    Donoviel, Michael S.
    Nouraldeen, Amr
    Tarver, James
    Fu, Qinghong
    Carlsen, Marianne
    Jessop, Theodore C.
    Zhang, Haiming
    Hazelwood, Jill
    Nguyen, Huy
    Baugh, Simon D. P.
    Gardyan, Michael
    Terranova, Kristen M.
    Barbosa, Joseph
    Yan, Jack
    Bednarz, Mark
    Layek, Suman
    Courtney, Lawrence F.
    Taylor, Jerry
    Digeorge-Foushee, Ann Marie
    Gopinathan, Suma
    Bruce, Debra
    Smith, Traci
    Moran, Liam
    O'Neill, Emily
    Kramer, Jeff
    Lai, Zhong
    Kimball, S. David
    Liu, Qingyun
    Sun, Weimei
    Yu, Sean
    Swaffield, Jonathan
    Wilson, Alan
    Main, Alan
    Carson, Kenneth G.
    Oravecz, Tamas
    Augeri, David J.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (13) : 3941 - 3953
  • [5] Direct quantitative analysis of lysophosphatidic acid molecular species by stable isotope dilution electrospray ionization liquid chromatography-mass spectrometry
    Baker, DL
    Desiderio, DM
    Miller, DD
    Tolley, B
    Tigyi, GJ
    [J]. ANALYTICAL BIOCHEMISTRY, 2001, 292 (02) : 287 - 295
  • [6] Expression of CD34 and Myf5 defines the majority of quiescent adult skeletal muscle satellite cells
    Beauchamp, JR
    Heslop, L
    Yu, DSW
    Tajbakhsh, S
    Kelly, RG
    Wernig, A
    Buckingham, ME
    Partridge, TA
    Zammit, PS
    [J]. JOURNAL OF CELL BIOLOGY, 2000, 151 (06) : 1221 - 1233
  • [7] Functional ability and muscle force in healthy children and ambulant Duchenne muscular dystrophy patients
    Beenakker, EAC
    Maurits, NM
    Fock, JM
    Brouwer, OF
    van der Hoeven, JH
    [J]. EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2005, 9 (06) : 387 - 393
  • [8] Sphingosine kinase/sphingosine 1-phosphate axis: a new player for insulin-like growth factor-1-induced myoblast differentiation
    Bernacchioni, Caterina
    Cencetti, Francesca
    Blescia, Sabrina
    Donati, Chiara
    Bruni, Paola
    [J]. SKELETAL MUSCLE, 2012, 2
  • [9] Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo
    Bodine, SC
    Stitt, TN
    Gonzalez, M
    Kline, WO
    Stover, GL
    Bauerlein, R
    Zlotchenko, E
    Scrimgeour, A
    Lawrence, JC
    Glass, DJ
    Yancopoulos, GD
    [J]. NATURE CELL BIOLOGY, 2001, 3 (11) : 1014 - 1019
  • [10] Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
    Brinkmann, Volker
    Billich, Andreas
    Baumruker, Thomas
    Heining, Peter
    Schmouder, Robert
    Francis, Gordon
    Aradhye, Shreeram
    Burtin, Pascale
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (11) : 883 - 897